BRIEF published on 07/24/2024 at 12:35, 8 months 10 days ago Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement Merger Financing Nasdaq Biopharmaceutical QTORIN™
BRIEF published on 07/24/2024 at 12:35, 8 months 10 days ago Palvella Therapeutics et Pieris Pharmaceuticals annoncent un accord de fusion définitif Financement Nasdaq Biopharmaceutique Fusionnement QTORIN™
PRESS RELEASE published on 07/24/2024 at 12:30, 8 months 10 days ago Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement Palvella Therapeutics, Inc. and Pieris Pharmaceuticals, Inc. announce a merger to focus on rare genetic skin diseases with QTORIN™ rapamycin. Joint webcast on July 24 at 8:30am ET Merger Clinical-stage Genetic Skin Diseases QTORIN™ Rapamycin FDA-approved Therapies
BRIEF published on 04/19/2024 at 18:15, 11 months 14 days ago Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split Reverse Stock Split Nasdaq Compliance Financial Regulation Pieris Pharmaceuticals Stock Adjustment
BRIEF published on 04/19/2024 at 18:15, 11 months 14 days ago Pieris Pharmaceuticals annonce un regroupement d'actions de 1 pour 80 Réglementation Financière Pieris Pharmaceutique Regroupement D'actions Inversé Conformité NASDAQ Ajustement Des Stocks
PRESS RELEASE published on 04/19/2024 at 18:10, 11 months 14 days ago Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split Pieris Pharmaceuticals, Inc. announces a 1-for-80 reverse stock split effective on April 22, 2024, to comply with Nasdaq listing requirements. No fractional shares will be issued Reverse Stock Split Compliance Nasdaq Pieris Pharmaceuticals Stockholder Ownership
BRIEF published on 03/27/2024 at 13:05, 1 year ago Pieris Pharmaceuticals Announces New Strategy to Maximize Financial Potential Shareholder Value Pieris Pharmaceuticals Strategic Reorganization Milestone Payments Royalty Potential
BRIEF published on 03/27/2024 at 13:05, 1 year ago Pieris Pharmaceuticals annonce une nouvelle stratégie pour maximiser le potentiel financier Valeur Pour Les Actionnaires Pieris Pharmaceutique Réorganisation Stratégique Paiements D'étape Potentiel De Redevances
PRESS RELEASE published on 03/27/2024 at 13:00, 1 year ago Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential Pieris Pharmaceuticals, Inc. announces strategic repositioning to maximize milestone and royalty potential from immuno-oncology assets. Cost-saving measures extend cash runway into 2027 Strategic Repositioning Cost-saving Measures Pieris Pharmaceuticals Milestone Payments Immuno-oncology Assets
Published on 04/04/2025 at 00:00, 36 minutes ago Onco-Innovations' Inka Health Completes Analytical Work for AstraZeneca Canada, Advancing Pharmaceutical Analytics and Leading to Key Studies at ISPOR 2025
Published on 04/03/2025 at 15:05, 9 hours 31 minutes ago Snowline Gold Closes Fully Subscribed C$20 Million Financing Of Flow-Through Shares
Published on 04/03/2025 at 15:00, 9 hours 36 minutes ago Kingstone Insurance Partners with Kyber Technologies Inc.
Published on 04/03/2025 at 15:00, 9 hours 36 minutes ago UniDoc Announces Debt Settlement and Renews Marketing Engagement
Published on 04/03/2025 at 15:00, 9 hours 36 minutes ago Xebra Brands’ Largest Shareholder Increases Stake as Company Explores Landmark Agricultural Agreement in Mexico
Published on 04/03/2025 at 18:46, 5 hours 50 minutes ago Monthly disclosure of the total number of shares and voting rights - March 2025
Published on 04/03/2025 at 18:46, 5 hours 50 minutes ago Déclaration mensuelle des actions et droits de vote – Mars 2025
Published on 04/03/2025 at 18:00, 6 hours 36 minutes ago LDC : Chiffre d'affaires 2024-2025 : 6,3 milliards d’euros, au-delà des objectifs.
